The impact of artificial intelligence on biomarker discovery

Artificial intelligence (AI) is transforming many fields, including healthcare and medicine. In biomarker discovery, AI algorithms have had a profound impact, thanks to their ability to derive insights from complex high-dimensional datasets and integrate multi-modal datatypes (such as omics, electronic health records, imaging or sensor and wearable data). However, despite the proliferation of AI-powered biomarkers, significant hurdles still remain in translating them to the clinic and driving adoption, including lack of population diversity, difficulties accessing harmonised data, costly and time-consuming clinical studies, evolving AI regulatory frameworks and absence of scalable diagnostic infrastructure. Here, we provide an overview of the AI toolkit available for biomarker discovery, and we discuss exciting examples of AI-powered biomarkers across therapeutic areas. Finally, we address the challenges ahead of us to ensure that these technologies reach patients and users globally and unlock a new era of fast innovation for precision medicine.

Authors

Institutions

Publication Details

Journal
Emerging Topics in Life Sciences
Published
2025-09-01
DOI
https://doi.org/10.1042/etls20243003
Citations
4
Primary Topic
Single-cell and spatial transcriptomics
Type
article
Field-Weighted Citation Impact
3.22
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The impact of artificial intelligence on biomarker discovery

Benjamin B. Sun, Paul G. O’Reilly, Constantin Cezar Petrescu, Jack Monahan et al.
4 citations
Emerging Topics in Life Sciences
Single-cell and spatial transcriptomics
3.22
article

The impact of artificial intelligence on biomarker discovery

Benjamin B. Sun, Paul G. O’Reilly, Constantin Cezar Petrescu, Jack Monahan, Daniel E. Martin‐Herranz, Mustafa Al Lail, Thomas M. Stubbs, HAMMAD JAVAID, Dimitrios Vitsios, Mahmoud Khasawneh, Deepak Ganta, Manik Garg, Lisa J. Schmunk, Leona McGirr
article en
4 citations

Abstract

Artificial intelligence (AI) is transforming many fields, including healthcare and medicine. In biomarker discovery, AI algorithms have had a profound impact, thanks to their ability to derive insights from complex high-dimensional datasets and integrate multi-modal datatypes (such as omics, electronic health records, imaging or sensor and wearable data). However, despite the proliferation of AI-powered biomarkers, significant hurdles still remain in translating them to the clinic and driving adoption, including lack of population diversity, difficulties accessing harmonised data, costly and time-consuming clinical studies, evolving AI regulatory frameworks and absence of scalable diagnostic infrastructure. Here, we provide an overview of the AI toolkit available for biomarker discovery, and we discuss exciting examples of AI-powered biomarkers across therapeutic areas. Finally, we address the challenges ahead of us to ensure that these technologies reach patients and users globally and unlock a new era of fast innovation for precision medicine.

Emerging Topics in Life SciencesVol. 8(2)
Texas A&M International University (US), Bristol-Myers Squibb (Germany) (DE), Trinity College (CA), Queens University (BD), AstraZeneca (Australia) (AU), Bristol-Myers Squibb (Sweden) (SE), Analytics Engines (United Kingdom) (GB), Biotronics 3D (United Kingdom) (GB)
Openalex Percentile: Top 8%
Single-cell and spatial transcriptomics
3.22
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.